Non-Small Cell Lung Cancer - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Non-Small Cell Lung Cancer > What Your Doctor is Reading About Non-Small Cell Lung Cancer > Clinical Trials

Clinical Trials

1. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.

Author: Garrido P; Gonzalez-Larriba JL; Insa A; Provencio M; Torres A; Isla D; Sanchez JM; Cardenal F; Domine M; Barcelo JR; Tarrazona V; Varela A; Aguilo R; Astudillo J; Muguruza I; Artal A; Hernando-Trancho F; Massuti B; Sanchez-Ronco M; Rosell R;
Institution: Hospital Ramon y Cajal, Madrid, Spain.
Journal: J Clin Oncol. 2007 Oct 20;25(30):4736-42.
Abstract URL: Click here to view abstract

2. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.

Author: Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M; Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M;
Institution: The First Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan. thirose-shw@umin.ac.jp
Journal: Cancer Chemother Pharmacol. 2006 Sep;58(3):361-7. Epub 2005 Dec 6.
Abstract URL: Click here to view abstract

3. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.

Author: Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y;
Institution: Department of Respiratory Medicine, National Hospital Organization Kyushu Medical Center, Chuo-ku, Fukuoka, Japan. ichiki@qmed.hosp.go.jp
Journal: Cancer Chemother Pharmacol. 2006 Sep;58(3):368-73. Epub 2006 Jan 4.
Abstract URL: Click here to view abstract

4. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.

Author: Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K;
Institution: Mary Crowley Medical Research Center, Baylor University Medical Center, Texas Oncology PA, Dallas, TX 75201, USA. jnemunaitis@mcmrc.com
Journal: Cancer Gene Ther. 2006 Jun;13(6):555-62.
Abstract URL: Click here to view abstract

5. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.

Author: Yamamoto N; Nishimura Y; Nakagawa K; Matsui K; Fukuoka M;
Institution: Medical Oncology, Kinki University School of Medicine, Osaka, Japan. n.yamamoto@scchr.jp
Journal: Cancer Chemother Pharmacol. 2006 Sep;58(3):285-91. Epub 2006 Jan 17.
Abstract URL: Click here to view abstract

6. High-dose proton beam therapy for Stage I non-small-cell lung cancer.

Author: Nihei K; Ogino T; Ishikura S; Nishimura H;
Institution: Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. knihei@east.ncc.go.jp
Journal: Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):107-11. Epub 2006 Feb 3.
Abstract URL: Click here to view abstract

7. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.

Author: Ritch P; Rudin CM; Bitran JD; Edelman MJ; Makalinao A; Irwin D; Lilenbaum R; Peterson P; John WJ;
Institution: Milwaukee Medical College, Milwaukee, USA.
Journal: Lung Cancer. 2006 May;52(2):173-80. Epub 2006 Feb 28.
Abstract URL: Click here to view abstract

8. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study.

Author: Roselli M; Mariotti S; Ferroni P; Laudisi A; Mineo D; Pompeo E; Ambrogi V; Mineo TC;
Institution: Medical Oncology, Department of Internal Medicine, Policlinico Tor Vergata University, Rome, Italy. mario.roselli@ptvonline.it
Journal: Int J Cancer. 2006 Aug 15;119(4):955-60.
Abstract URL: Click here to view abstract

9. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma.

Author: Koukourakis MI; Patlakas G; Froudarakis ME; Kyrgias G; Skarlatos J; Abatzoglou I; Bougioukas G; Bouros D;
Institution: Department of Radiotherapy/Oncology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece. targ@her.forthnet.gr
Journal: Anticancer Res. 2007 Sep-Oct;27(5B):3625-31.
Abstract URL: Click here to view abstract

10. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.

Author: Gilligan D; Nicolson M; Smith I; Groen H; Dalesio O; Goldstraw P; Hatton M; Hopwood P; Manegold C; Schramel F; Smit H; van Meerbeeck J; Nankivell M; Parmar M; Pugh C; Stephens R;
Institution: Addenbrooke's Hospital, Cambridge, UK.
Journal: Lancet. 2007 Jun 9;369(9577):1929-37.
Abstract URL: Click here to view abstract

11. Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer.

Author: Shirai T; Hirose T; Noda M; Ando K; Ishida H; Hosaka T; Ozawa T; Okuda K; Ohnishi T; Ohmori T; Horichi N; Adachi M;
Institution: The First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan. alicelov@t.toshima.ne.jp
Journal: Lung Cancer. 2006 May;52(2):181-7. Epub 2006 Mar 24.
Abstract URL: Click here to view abstract

12. A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.

Author: Pallis AG; Agelidou A; Papakotoulas P; Tsaroucha A; Agelidou M; Agelaki S; Androulakis N; Vamvakas L; Gerogianni A; Kotsakis A; Kentepozidis N; Georgoulias V;
Institution: Department of Medical Oncology, University Hospital of Heraklion, Greece.
Journal: Lung Cancer. 2006 May;52(2):165-71. Epub 2006 Mar 24.
Abstract URL: Click here to view abstract

13. Cisplatin plus continuous infusion vinorelbine for the treatment of advanced non-small cell lung cancer: a phase I-II study.

Author: Cobo-Dols M; Gil-Calle S; Villar-Chamorro E; Ales-Diaz I; Carabantes-Ocon F; Alcalde-Garcia J; Gutierrez-Calderon V; Montesa-Pino A; Breton-Garcia JJ; Benavides-Orgaz M;
Institution: Medical Oncology Section, Hospital Regional Universitario Carlos Haya, Malaga, Spain. manuelcobodols@yahoo.es
Journal: Clin Transl Oncol. 2006 Jul;8(7):519-24.
Abstract URL: Click here to view abstract

14. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).

Author: Kudoh S; Takeda K; Nakagawa K; Takada M; Katakami N; Matsui K; Shinkai T; Sawa T; Goto I; Semba H; Seto T; Ando M; Satoh T; Yoshimura N; Negoro S; Fukuoka M;
Institution: Department of Respiratory Medicine, Osaka City University Medical School, Osaka, Japan. shinzohykudoh@med.osaka-cu.ac.jp
Journal: J Clin Oncol. 2006 Aug 1;24(22):3657-63.
Abstract URL: Click here to view abstract

15. Phase I/II study of paclitaxel + carboplatin for refractory or recurrent non-small cell lung cancer.

Author: Gemma A; Seike M; Kosaihira S; Minegishi Y; Noro R; Nara M; Hosomi Y; Okano T; Kokubo Y; Yoshimura A; Shibuya M; Kudoh S;
Institution: Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, Tokyo, Japan. agemma@nms.ac.jp
Journal: Anticancer Res. 2006 Jul-Aug;26(4B):3083-7.
Abstract URL: Click here to view abstract

16. Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II study.

Author: Planchard D; Bourgeois H; Adoun M; Paitel JF; Blanc P; Genet D; Ferru A; Meurice JC; Deletage C; Tourani JM;
Institution: Pneumology Unit, University Hospital of Poitiers, Poitiers, France. d.planchard@chu-poitiers.fr
Journal: Am J Clin Oncol. 2006 Aug;29(4):345-51.
Abstract URL: Click here to view abstract

17. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

Author: Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T;
Institution: Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging, and Cancer, Tohoku University, 4-1, Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. akinoue@idac.tohoku.ac.jp
Journal: J Clin Oncol. 2006 Jul 20;24(21):3340-6. Epub 2006 Jun 19.
Abstract URL: Click here to view abstract

18. Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy.

Author: Kramer GW; Legrand CL; van Schil P; Uitterhoeve L; Smit EF; Schramel F; Biesma B; Tjan-Heijnen V; van Zandwijk N; Splinter T; Giaccone G; van Meerbeeck JP;
Institution: Radiotherapeutic Institute ARTI, Wagnerlaan 47, 6815 Arnhem, The Netherlands.
Journal: Eur J Cancer. 2006 Jul;42(10):1391-8.
Abstract URL: Click here to view abstract

19. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.

Author: Molina JR; Nikcevich D; Hillman S; Geyer S; Drevyanko T; Jett J; Verdirame J; Tazelaar H; Rowland K; Wos E; Kutteh L; Nair S; Fitch T; Flynn P; Stella P; Adjei AA;
Institution: Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Journal: Cancer Invest. 2006 Jun-Jul;24(4):382-9.
Abstract URL: Click here to view abstract

20. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

Author: Brodowicz T; Krzakowski M; Zwitter M; Tzekova V; Ramlau R; Ghilezan N; Ciuleanu T; Cucevic B; Gyurkovits K; Ulsperger E; Jassem J; Grgic M; Saip P; Szilasi M; Wiltschke C; Wagnerova M; Oskina N; Soldatenkova V; Zielinski C; Wenczl M;
Institution: Medical University Hospital, Vienna, Austria.
Journal: Lung Cancer. 2006 May;52(2):155-63. Epub 2006 Mar 29.
Abstract URL: Click here to view abstract

21. Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study.

Author: Bennouna J; Breton JL; Tourani JM; Ottensmeier C; O'Brien M; Kosmidis P; Huat TE; Pinel MC; Colin C; Douillard JY;
Institution: Centre Rene Gauducheau, Boulevard Jacques Monod, Saint-Herblain 44805, France. j-bennouna@nantes.fnclcc.fr
Journal: Br J Cancer. 2006 May 22;94(10):1383-8.
Abstract URL: Click here to view abstract

22. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.

Author: Suzuki R; Hasegawa Y; Baba K; Saka H; Saito H; Taniguchi H; Yamamoto M; Matsumoto S; Kato K; Oishi T; Imaizumi K; Shimokata K;
Institution: Toyohashi Municipal Hospital, 50 Hachiken-nishi, Aotake, Toyohashi, Aichi 441-8570, Japan. rsuzuki-alg@umin.ac.jp
Journal: Br J Cancer. 2006 Jun 5;94(11):1599-603.
Abstract URL: Click here to view abstract

23. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.

Author: Ramlau R; Gervais R; Krzakowski M; von Pawel J; Kaukel E; Abratt RP; Dharan B; Grotzinger KM; Ross G; Dane G; Shepherd FA;
Institution: Regional Lung Disease Centre, Oncology Department, Poznan, Poland. rramlau@wcchpig.pl
Journal: J Clin Oncol. 2006 Jun 20;24(18):2800-7. Epub 2006 May 8.
Abstract URL: Click here to view abstract

24. Phase I/II study of gemcitabine and epirubicine in stage IIIB-IV non small cell lung cancer.

Author: Illiano A; Battiloro C; Formato R; Danilo R; Tortoriello A; Caponigro F; Iaffaioli RV;
Institution: Pneumoncology Monaldi H., Naples, Italy.
Journal: Front Biosci. 2006 Sep 1;11:2349-53.
Abstract URL: Click here to view abstract

25. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).

Author: Biesma B; Manegold C; Smit HJ; Willems L; Legrand C; Passioukov A; van Meerbeeck JP; Giaccone G;
Institution: Afdeling Longziekten, Jeroen Bosch Ziekenhuis, Nieuwstraat 34, 5211 NL's-Hertogenbosch, The Netherlands. b.biesma@jbz.nl
Journal: Eur J Cancer. 2006 Jul;42(10):1399-406. Epub 2006 Jun 8.
Abstract URL: Click here to view abstract

26. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies.

Author: Gridelli C; Maione P; Illiano A; Piantedosi FV; Favaretto A; Bearz A; Robbiati SF; Filipazzi V; Lorusso V; Carrozza F; Iaffaioli RV; Manzione L; Gallo C; Morabito A; Perrone F;
Institution: Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy. cgridelli@libero.it
Journal: J Clin Oncol. 2007 Oct 10;25(29):4663-9.
Abstract URL: Click here to view abstract

27. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.

Author: Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
Institution: National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada.
Journal: J Clin Oncol. 2008 Jan 1;26(1):54-9.
Abstract URL: Click here to view abstract

28. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

Author: Ramalingam SS; Dahlberg SE; Langer CJ; Gray R; Belani CP; Brahmer JR; Sandler AB; Schiller JH; Johnson DH;
Institution: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA. suresh.ramalingam@emory.edu
Journal: J Clin Oncol. 2008 Jan 1;26(1):60-5.
Abstract URL: Click here to view abstract

29. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.

Author: Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR;
Institution: Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
Journal: J Thorac Oncol. 2008 Jan;3(1):68-74.
Abstract URL: Click here to view abstract

30. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Author: Lara PN Jr; Redman MW; Kelly K; Edelman MJ; Williamson SK; Crowley JJ; Gandara DR;
Institution: University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu
Journal: J Clin Oncol. 2008 Jan 20;26(3):463-7.
Abstract URL: Click here to view abstract

31. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.

Author: Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ;
Institution: Penn State Cancer Institute, H072, 500 University Drive, PO Box 850, Hershey, PA 77030, USA. cbelani@psu.edu
Journal: J Clin Oncol. 2008 Jan 20;26(3):468-73.
Abstract URL: Click here to view abstract

32. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

Author: Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG;
Institution: Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. rizvin@mskcc.org
Journal: J Clin Oncol. 2008 Feb 1;26(4):639-43.
Abstract URL: Click here to view abstract

33. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806.

Author: Kunitoh H; Kato H; Tsuboi M; Shibata T; Asamura H; Ichonose Y; Katakami N; Nagai K; Mitsudomi T; Matsumura A; Nakagawa K; Tada H; Saijo N;
Institution: Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. hkkunito@ncc.go.jp
Journal: J Clin Oncol. 2008 Feb 1;26(4):644-9.
Abstract URL: Click here to view abstract

34. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

Author: Butts CA; Bodkin D; Middleman EL; Englund CW; Ellison D; Alam Y; Kreisman H; Graze P; Maher J; Ross HJ; Ellis PM; McNulty W; Kaplan E; Pautret V; Weber MR; Shepherd FA;
Institution: Cross Cancer Institute, 11560 University Ave, Edmonton, Alberta, Canada. charlesb@cancerboard.ab.ca
Journal: J Clin Oncol. 2007 Dec 20;25(36):5777-84.
Abstract URL: Click here to view abstract

35. Quality of life and survival in the 2 years after surgery for non small-cell lung cancer.

Author: Kenny PM; King MT; Viney RC; Boyer MJ; Pollicino CA; McLean JM; Fulham MJ; McCaughan BC;
Institution: Centre for Health Economics Research and Evaluation, University of Technology, Sydney, PO Box 123, Broadway, Sydney, New South Wales 2007, Australia.: patsy.kenny@chere.uts.edu.au
Journal: J Clin Oncol. 2008 Jan 10;26(2):233-41. Epub 2007 Dec 17.
Abstract URL: Click here to view abstract

36. Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy.

Author: Chou KT; Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J;
Institution: Chest Department, Taipei Veterans General Hospital, Taipei, Taiwan.
Journal: Lung Cancer. 2008 Jan;59(1):64-8. Epub 2007 Aug 30.
Abstract URL: Click here to view abstract

37. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.

Author: Georgoulias V; Androulakis N; Kotsakis A; Hatzidaki D; Syrigos K; Polyzos A; Agelidou A; Varthalitis I; Ziras N; Agelidou M; Chandrinos V; Boukovinas I; Geroyianni A; Vamvakas L; Mavroudis D;
Institution: The Hellenic Oncology Research Group (HORG), Athens, Greece. georgsec@med.uoc.gr
Journal: Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.
Abstract URL: Click here to view abstract

38. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.

Author: Kim DW; Kim SY; Kim HK; Kim SW; Shin SW; Kim JS; Park K; Lee MY; Heo DS;
Institution: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Journal: Ann Oncol. 2007 Dec;18(12):2009-14. Epub 2007 Sep 4.
Abstract URL: Click here to view abstract

39. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer.

Author: Werner-Wasik M; Swann RS; Bradley J; Graham M; Emami B; Purdy J; Sause W;
Institution: Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, PA, USA. maria.werner-wasik@jeffersonhospital.org
Journal: Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):385-90. Epub 2007 Sep 14.
Abstract URL: Click here to view abstract

40. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.

Author: Kosmidis PA; Kalofonos HP; Christodoulou C; Syrigos K; Makatsoris T; Skarlos D; Bakogiannis C; Nicolaides C; Bafaloukos D; Bamias A; Samantas E; Xiros N; Boukovinas I; Fountzilas G; Dimopoulos MA;
Institution: Department of Medical Oncology, Hygeia Hospital, Athens, Greece. parkosmi@otenet.gr
Journal: Ann Oncol. 2008 Jan;19(1):115-22. Epub 2007 Oct 15.
Abstract URL: Click here to view abstract

41. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

Author: Rosell R; Robinet G; Szczesna A; Ramlau R; Constenla M; Mennecier BC; Pfeifer W; O'Byrne KJ; Welte T; Kolb R; Pirker R; Chemaissani A; Perol M; Ranson MR; Ellis PA; Pilz K; Reck M;
Institution: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. rrosell@ico.scs.es
Journal: Ann Oncol. 2008 Feb;19(2):362-9. Epub 2007 Oct 17.
Abstract URL: Click here to view abstract

42. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Author: Socinski MA; Novello S; Brahmer JR; Rosell R; Sanchez JM; Belani CP; Govindan R; Atkins JN; Gillenwater HH; Pallares C; Tye L; Selaru P; Chao RC; Scagliotti GV;
Institution: Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB# 7305, Chapel Hill, NC 27599, USA. socinski@med.unc.edu
Journal: J Clin Oncol. 2008 Feb 1;26(4):650-6.
Abstract URL: Click here to view abstract

43. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.

Author: Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH;
Institution: Yonsei Cancer Center, Seoul, Korea.
Journal: J Clin Oncol. 2007 Jun 20;25(18):2528-33.
Abstract URL: Click here to view abstract

44. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.

Author: Bolonaki I; Kotsakis A; Papadimitraki E; Aggouraki D; Konsolakis G; Vagia A; Christophylakis C; Nikoloudi I; Magganas E; Galanis A; Cordopatis P; Kosmatopoulos K; Georgoulias V; Mavroudis D;
Institution: Department of Transfusion Medicine, University General Hospital of Heraklion, Heraklion, Crete, Greece.
Journal: J Clin Oncol. 2007 Jul 1;25(19):2727-34.
Abstract URL: Click here to view abstract

45. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

Author: Vansteenkiste J; Lara PN Jr; Le Chevalier T; Breton JL; Bonomi P; Sandler AB; Socinski MA; Delbaldo C; McHenry B; Lebwohl D; Peck R; Edelman M;
Institution: Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium. johan.vansteenkiste@uz.kuleuven.ac.be
Journal: J Clin Oncol. 2007 Aug 10;25(23):3448-55. Epub 2007 Jul 2.
Abstract URL: Click here to view abstract

46. A prospective phase II study of a new treatment protocol for NSCLC combined with preoperative mediastinoscopy and chemotherapy.

Author: Nakajima T; Kimura H; Suzuki M; Wada H; Ando S; Iida T; Sekine Y; Fujisawa T;
Institution: Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Journal: Thorac Cardiovasc Surg. 2007 Aug;55(5):317-21.
Abstract URL: Click here to view abstract

47. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.

Author: O'Byrne KJ; Danson S; Dunlop D; Botwood N; Taguchi F; Carbone D; Ranson M;
Institution: St James's Hospital, Dublin, Ireland. kobyrne@stjames.ie
Journal: J Clin Oncol. 2007 Aug 1;25(22):3266-73.
Abstract URL: Click here to view abstract

48. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

Author: Janne PA; von Pawel J; Cohen RB; Crino L; Butts CA; Olson SS; Eiseman IA; Chiappori AA; Yeap BY; Lenehan PF; Dasse K; Sheeran M; Bonomi PD;
Institution: Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. pjanne@partners.org
Journal: J Clin Oncol. 2007 Sep 1;25(25):3936-44.
Abstract URL: Click here to view abstract

49. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer.

Author: Sarkaria JN; Schwingler P; Schild SE; Grogan PT; Mladek AC; Mandrekar SJ; Tan AD; Kobayashi T; Marks RS; Kita H; Miller RC; Limper AH; Leof EB;
Institution: Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA. sarkaria.jann@mayo.edu
Journal: J Thorac Oncol. 2007 Aug;2(8):751-7.
Abstract URL: Click here to view abstract

50. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.

Author: Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R;
Institution: Gravina Hospital, Oncology Unit, Caltagirone, Italy.
Journal: Anticancer Drugs. 2007 Jul;18(6):713-9.
Abstract URL: Click here to view abstract

51. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC).

Author: Patel SH; Ajlouni M; Chapman R; Lu M; Movsas B; Kim JH;
Institution: Department of Radiation Oncology, Henry Ford Hospital, Detroit, Michigan 48202, USA. spatel3@hfhs.org
Journal: J Thorac Oncol. 2007 Sep;2(9):831-7.
Abstract URL: Click here to view abstract

52. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

Author: Spigel DR; Hainsworth JD; Simons L; Meng C; Burris HA 3rd; Yardley DA; Grapski R; Schreeder M; Mallidi PV; Greco FA;
Institution: Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA.
Journal: J Thorac Oncol. 2007 Sep;2(9):854-61.
Abstract URL: Click here to view abstract

53. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

Author: Heymach JV; Johnson BE; Prager D; Csada E; Roubec J; Pesek M; Spasova I; Belani CP; Bodrogi I; Gadgeel S; Kennedy SJ; Hou J; Herbst RS;
Institution: Dana-Farber Cancer Institute, Boston, MA, USA.
Journal: J Clin Oncol. 2007 Sep 20;25(27):4270-7.
Abstract URL: Click here to view abstract

54. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

Author: Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A;
Institution: The M.D. Anderson Cancer Center, Houston, TX 77030, USA. rherbst@mdanderson.org
Journal: J Clin Oncol. 2007 Oct 20;25(30):4743-50. Epub 2007 Oct 1.
Abstract URL: Click here to view abstract

55. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.

Author: Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L;
Institution: Division of Medical Oncology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada. vera.hirsh@muhc.mcgill.ca
Journal: J Thorac Oncol. 2007 Oct;2(10):927-32.
Abstract URL: Click here to view abstract

56. Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency.

Author: Mitsumori M; Zeng ZF; Oliynychenko P; Park JH; Choi IB; Tatsuzaki H; Tanaka Y; Hiraoka M;
Institution: Department of Therapeutic Radiology and Oncology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. mitsumo@kuhp.kyoto-u.ac.jp
Journal: Int J Clin Oncol. 2007 Jun;12(3):192-8. Epub 2007 Jun 27.
Abstract URL: Click here to view abstract

57. Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients.

Author: Temel JS; Jackson VA; Billings JA; Dahlin C; Block SD; Buss MK; Ostler P; Fidias P; Muzikansky A; Greer JA; Pirl WF; Lynch TJ;
Institution: Massachusetts General Hospital, Boston, MA 02114, USA. jtemel@partners.org
Journal: J Clin Oncol. 2007 Jun 10;25(17):2377-82.
Abstract URL: Click here to view abstract

58. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.

Author: Yuan S; Sun X; Li M; Yu J; Ren R; Yu Y; Li J; Liu X; Wang R; Li B; Kong L; Yin Y;
Institution: Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, China.
Journal: Am J Clin Oncol. 2007 Jun;30(3):239-44.
Abstract URL: Click here to view abstract

59. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.

Author: Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D;
Institution: Mount Sinai Cancer Center; 4306 Alton Road; Miami Beach, FL 33140, USA. rlilenbaum@aptiumoncology.com
Journal: J Clin Oncol. 2008 Feb 20;26(6):863-9.
Abstract URL: Click here to view abstract

60. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.

Author: Tabata M; Kozuki T; Ueoka H; Kiura K; Harita S; Tada A; Shibayama T; Takigawa N; Yonei T; Gemba K; Segawa Y; Kishino D; Tada S; Hiraki S; Tanimoto M;
Institution: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Journal: Cancer Chemother Pharmacol. 2007 Jun;60(1):53-9. Epub 2006 Sep 29.
Abstract URL: Click here to view abstract

61. Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.

Author: Dowlati A; Subbiah S; Cooney M; Rutherford K; Mekhail T; Fu P; Chapman R; Ness A; Cortas T; Saltzman J; Levitan N; Warren G;
Institution: Division of Hematology/Oncology, Case Western Reserve University and University Hospitals of Cleveland, CASE Comprehensive Cancer Center, Cleveland, Ohio 44106, USA. afshin.dowlati@case.edu
Journal: Lung Cancer. 2007 Jun;56(3):377-81. Epub 2007 Feb 27.
Abstract URL: Click here to view abstract

62. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.

Author: Takeda K; Takifuji N; Negoro S; Furuse K; Nakamura S; Takada Y; Hoso T; Hayasaka S; Nakano T; Araki J; Senba H; Iwami F; Yamaji Y; Fukuoka M; Ikegami H;
Institution: Department of Clinical Oncology, Osaka City General Hospital, 2-13-22, Miyakojimahondohri, Osaka 5340021, Japan. kkk-take@ga2.so-net.ne.jp
Journal: Invest New Drugs. 2007 Aug;25(4):377-83. Epub 2007 Mar 10.
Abstract URL: Click here to view abstract

63. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.

Author: Hata M; Tokuuye K; Kagei K; Sugahara S; Nakayama H; Fukumitsu N; Hashimoto T; Mizumoto M; Ohara K; Akine Y;
Institution: Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan. mhata@syd.odn.ne.jp
Journal: Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):786-93. Epub 2007 Mar 26.
Abstract URL: Click here to view abstract

64. Closeness to death and quality of life in advanced lung cancer patients.

Author: Brown S; Thorpe H; Napp V; Brown J;
Institution: Clinical Trials Research Unit, University of Leeds, 17 Springfield Mount, Leeds LS2 9NG, UK. s.brown@leeds.ac.uk
Journal: Clin Oncol (R Coll Radiol). 2007 Jun;19(5):341-8. Epub 2007 Mar 26.
Abstract URL: Click here to view abstract

65. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.

Author: Gridelli C; Gallo C; Ceribelli A; Gebbia V; Gamucci T; Ciardiello F; Carozza F; Favaretto A; Daniele B; Galetta D; Barbera S; Rosetti F; Rossi A; Maione P; Cognetti F; Testa A; Di Maio M; Morabito A; Perrone F;
Institution: Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy. cgridelli@libero.it
Journal: Lancet Oncol. 2007 Jun;8(6):500-12.
Abstract URL: Click here to view abstract

66. Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial.

Author: De Ruysscher D; Bussink J; Rodrigus P; Kessels A; Dirx M; Houben R; Wanders R;
Institution: MAASTRO Clinic, Maastricht, The Netherlands. dirk.deruysscher@maastro.nl
Journal: Radiother Oncol. 2007 Jul;84(1):23-5. Epub 2007 May 25.
Abstract URL: Click here to view abstract

67. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer.

Author: Schild SE; Mandrekar SJ; Jatoi A; McGinnis WL; Stella PJ; Deming RL; Jett JR; Garces YI; Allen KL; Adjei AA;
Institution: Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA. sschild@mayo.edu
Journal: Cancer. 2007 Jul 15;110(2):363-8.
Abstract URL: Click here to view abstract

68. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6.

Author: Hesketh PJ; Lilenbaum RC; Chansky K; Dowlati A; Graham P; Chapman RA; Crowley JJ; Gandara DR;
Institution: Caritas St. Elizabeth's Medical Center of Boston, Boston, Massachusetts 02135, USA. phesketh@massmed.org
Journal: J Thorac Oncol. 2007 Jun;2(6):494-8.
Abstract URL: Click here to view abstract

69. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.

Author: Riedel RF; Andrews C; Garst J; Dunphy F; Herndon JE 2nd; Blackwell S; Barbour S; Crawford J;
Institution: Ruth and Herman Albert Thoracic Oncology Program, Duke University Medical Center, Durham, North Carolina 27710, USA.
Journal: J Thorac Oncol. 2007 Jun;2(6):520-5.
Abstract URL: Click here to view abstract

70. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.

Author: Yoneda KY; Shelton DK; Beckett LA; Gandara DR;
Institution: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California 95817, USA. kyyoneda@ucdavis.edu
Journal: J Thorac Oncol. 2007 Jun;2(6):537-43.
Abstract URL: Click here to view abstract

71. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.

Author: Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH;
Institution: Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China.
Journal: Cancer Chemother Pharmacol. 2007 Sep;60(4):601-7. Epub 2007 Jun 5.
Abstract URL: Click here to view abstract

72. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.

Author: Weiss GJ; Vokes EE; Bunn PA Jr; Magree L; Rusk J; Albert D; Kelly K;
Institution: TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, AZ, USA.
Journal: J Thorac Oncol. 2007 Oct;2(10):933-8.
Abstract URL: Click here to view abstract

73. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.

Author: Belderbos JS; Heemsbergen WD; De Jaeger K; Baas P; Lebesque JV;
Institution: Department of Radiation Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. j.belderbos@nki.nl
Journal: Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):126-34.
Abstract URL: Click here to view abstract

74. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

Author: Hanna N; Lilenbaum R; Ansari R; Lynch T; Govindan R; Janne PA; Bonomi P;
Institution: Indiana University, Indianapolis, USA. nhanna@iupui.edu
Journal: J Clin Oncol. 2006 Nov 20;24(33):5253-8.
Abstract URL: Click here to view abstract

75. Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.

Author: Akerley W; Safran H; Zaner K; Ready N; Mega T; Kennedy T; Akerley W; Safran H; Zaner K; Ready N; Mega T; Kennedy T;
Institution: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84115, USA. akerley@HCI.utah.edu
Journal: Cancer. 2006 Sep 1;107(5):1050-4.
Abstract URL: Click here to view abstract

76. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.

Author: Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI; Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI;
Institution: Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom. arc@macunlimited.net
Journal: Cancer. 2006 Sep 15;107(6):1321-30.
Abstract URL: Click here to view abstract

77. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Author: Olaussen KA; Dunant A; Fouret P; Brambilla E; Andre F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC; Olaussen KA; Dunant A; Fouret P; Brambilla E; Andre F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
Institution: Laboratory of Radiobiology and Oncology, Commissariat a l'Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris, France.
Journal: N Engl J Med. 2006 Sep 7;355(10):983-91.
Abstract URL: Click here to view abstract

78. Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases.

Author: Rogers LR; Rock JP; Sills AK; Vogelbaum MA; Suh JH; Ellis TL; Stieber VW; Asher AL; Fraser RW; Billingsley JS; Lewis P; Schellingerhout D; Shaw EG; Rogers LR; Rock JP; Sills AK; Vogelbaum MA; Suh JH; Ellis TL; Stieber VW; Asher AL; Fraser RW; Billingsley JS; Lewis P; Schellingerhout D; Shaw EG;
Institution: Department of Neurology and Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48109-0316, USA. lisaroge@umich.edu
Journal: J Neurosurg. 2006 Sep;105(3):375-84.
Abstract URL: Click here to view abstract

79. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study.

Author: Okada M; Koike T; Higashiyama M; Yamato Y; Kodama K; Tsubota N; Okada M; Koike T; Higashiyama M; Yamato Y; Kodama K; Tsubota N;
Institution: Department of Thoracic Surgery, Hyogo Medical Center for Adults, Akashi City, Hyogo, Japan. morihito1217jp@aol.com
Journal: J Thorac Cardiovasc Surg. 2006 Oct;132(4):769-75.
Abstract URL: Click here to view abstract

80. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.

Author: Milton DT; Azzoli CG; Heelan RT; Venkatraman E; Gomez JE; Kris MG; Krug LM; Pao W; Rizvi NA; Dunne M; Miller VA; Milton DT; Azzoli CG; Heelan RT; Venkatraman E; Gomez JE; Kris MG; Krug LM; Pao W; Rizvi NA; Dunne M; Miller VA;
Institution: Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA.
Journal: Cancer. 2006 Sep 1;107(5):1034-41.
Abstract URL: Click here to view abstract

81. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Author: Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH; Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH; Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH;
Institution: Vanderbilt University, Nashville, TN, USA. sandler@vanderbilt.edu
Journal: N Engl J Med. 2006 Dec 14;355(24):2542-50.
Abstract URL: Click here to view abstract

82. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.

Author: Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J; Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J;
Institution: Division of Oncology and Pulmonology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Journal: Cancer. 2007 Feb 15;109(4):732-40.
Abstract URL: Click here to view abstract

83. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.

Author: Yokomise H; Gotoh M; Okamoto T; Yamamoto Y; Ishikawa S; Nakashima T; Masuya D; Liu D; Huang CL; Yokomise H; Gotoh M; Okamoto T; Yamamoto Y; Ishikawa S; Nakashima T; Masuya D; Liu D; Huang CL;
Institution: Second Department of Surgery, Faculty of Medicine, Kagawa University, Miki-cho, Japan. yokomise@kms.ac.jp
Journal: J Thorac Cardiovasc Surg. 2007 May;133(5):1179-85.
Abstract URL: Click here to view abstract

84. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.

Author: d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD; d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD;
Institution: Jefferson Medical College, Division of Cardiothoracic Surgery, Thomas Jefferson University, Philadelphia, Pa 19107, USA. thomas.damato@jefferson.edu
Journal: J Thorac Cardiovasc Surg. 2007 Feb;133(2):352-63. Epub 2007 Jan 9.
Abstract URL: Click here to view abstract

85. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology.

Author: Moscetti L; Nelli F; Felici A; Rinaldi M; De Santis S; D'Auria G; Mansueto G; Tonini G; Sperduti I; Pollera FC; Moscetti L; Nelli F; Felici A; Rinaldi M; De Santis S; D'Auria G; Mansueto G; Tonini G; Sperduti I; Pollera FC;
Institution: Department of Medical Oncology, Central Hospital of Belcolle, Viterbo, Italy.
Journal: Cancer. 2007 Jan 15;109(2):274-81.
Abstract URL: Click here to view abstract

86. Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.

Author: Ceribelli A; Pino MS; Gelibter AJ; Milella M; Cecere FL; Caterino M; Facciolo F; Mirri A; Cognetti F; Ceribelli A; Pino MS; Gelibter AJ; Milella M; Cecere FL; Caterino M; Facciolo F; Mirri A; Cognetti F;
Institution: Division of Medical Oncology "A," Regina Elena Cancer Institute, Rome, Italy. aceribelli@yahoo.com
Journal: Cancer. 2007 Feb 15;109(4):727-31.
Abstract URL: Click here to view abstract

87. Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).

Author: Phernambucq EC; Biesma B; Smit EF; Paul MA; vd Tol A; Schramel FM; Bolhuis RJ; Postmus PE;
Institution: Department of Pulmonary Diseases, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands.
Journal: Br J Cancer. 2006 Aug 21;95(4):470-4. Epub 2006 Aug 8.
Abstract URL: Click here to view abstract

88. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.

Author: Socinski MA; Ivanova A; Bakri K; Wall J; Baggstrom MQ; Hensing TA; Mears A; Tynan M; Beaumont J; Peterman AH; Niell HB;
Institution: Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. socinski@med.unc.edu
Journal: Ann Oncol. 2006 Jan;17(1):104-9. Epub 2005 Oct 25.
Abstract URL: Click here to view abstract

89. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe francais de pneumo-cancerologie).

Author: Thomas P; Robinet G; Gouva S; Fournel P; Lena H; Le Caer H; Perol M; Berard H; Bombaron P; Vergnenegre A; Kleisbauer JP;
Institution: Service d'Oncologie Respiratoire, Hopital Sainte-Marguerite, 270 Bd Sainte-Marguerite, 13009 Marseille, and Service de Pneumologie, Hopital Nord, Centre Hospitalier Universitaire de Saint-Etienne, France. pascal.thomas@ch-gap.fr
Journal: Lung Cancer. 2006 Jan;51(1):105-14. Epub 2005 Nov 28.
Abstract URL: Click here to view abstract

90. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.

Author: Recchia F; Saggio G; Nuzzo A; Biondi E; Di Blasio A; Cesta A; Candeloro G; Alesse E; Rea S;
Institution: Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy. frecchia1946@libero.it
Journal: J Immunother. 2006 Jan-Feb;29(1):87-94.
Abstract URL: Click here to view abstract

91. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.

Author: Niho S; Kubota K; Goto K; Yoh K; Ohmatsu H; Kakinuma R; Saijo N; Nishiwaki Y;
Institution: Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. siniho@east.ncc.go.jp
Journal: J Clin Oncol. 2006 Jan 1;24(1):64-9.
Abstract URL: Click here to view abstract

92. Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma.

Author: Han JY; Lim HS; Lee DH; Ju SY; Lee SY; Kim HY; Park YH; Park CG; Lee JS;
Institution: Research Institute and Hospital, Center for Lung Cancer, National Cancer Center, Goyang, Korea.
Journal: Cancer. 2006 Feb 15;106(4):873-80.
Abstract URL: Click here to view abstract

93. Multimodality treatment of unresectable stage III non-small cell lung cancer: interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy.

Author: Galetta D; Cesario A; Margaritora S; Porziella V; Piraino A; D'Angelillo RM; Gambacorta MA; Ramella S; Trodella L; Valente S; Corbo GM; Macis G; Mule A; Cardaci V; Sterzi S; Granone P; Russo P;
Institution: Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy.
Journal: J Thorac Cardiovasc Surg. 2006 Feb;131(2):314-21. Epub 2006 Jan 18.
Abstract URL: Click here to view abstract

94. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.

Author: Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG;
Institution: Medical Oncology Department, SS Giovanni and Paolo Hospital, Venezia, Italy. adriano.paccagnella@ulss12.ve.it
Journal: J Clin Oncol. 2006 Feb 1;24(4):681-7.
Abstract URL: Click here to view abstract

95. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.

Author: Yasuda H; Yamaya M; Nakayama K; Sasaki T; Ebihara S; Kanda A; Asada M; Inoue D; Suzuki T; Okazaki T; Takahashi H; Yoshida M; Kaneta T; Ishizawa K; Yamanda S; Tomita N; Yamasaki M; Kikuchi A; Kubo H; Sasaki H;
Institution: Department of Geriatric and Respiratory Medicine, Tohoku University School of Medicine, Seiryo-machi, Aoba-ku, Sendai, Japan. yasuda@geriat.med.tohoku.ac.jp
Journal: J Clin Oncol. 2006 Feb 1;24(4):688-94.
Abstract URL: Click here to view abstract

96. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Author: Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
Institution: Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada. andrea.bezjak@rmp.uhn.on.ca
Journal: J Clin Oncol. 2006 Aug 20;24(24):3831-7.
Abstract URL: Click here to view abstract

97. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Author: Douillard JY; Rosell R; De Lena M; Carpagnano F; Ramlau R; Gonzales-Larriba JL; Grodzki T; Pereira JR; Le Groumellec A; Lorusso V; Clary C; Torres AJ; Dahabreh J; Souquet PJ; Astudillo J; Fournel P; Artal-Cortes A; Jassem J; Koubkova L; His P; Riggi M; Hurteloup P;
Institution: Centre Rene Gauducheau, Nantes, France. jy-douillard@nantes.fnclcc.fr
Journal: Lancet Oncol. 2006 Sep;7(9):719-27.
Abstract URL: Click here to view abstract

98. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.

Author: Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H;
Institution: Mary Crowley Medical Research Center/Texas Oncology Professional Association, Dallas, TX, USA. jnemunaitis@mcmrc.com
Journal: J Clin Oncol. 2006 Oct 10;24(29):4721-30. Epub 2006 Sep 11.
Abstract URL: Click here to view abstract

99. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.

Author: White SC; Lorigan P; Margison GP; Margison JM; Martin F; Thatcher N; Anderson H; Ranson M;
Institution: Christie Hospital NHS Trust, Manchester, UK. shane.white@austin.org.au
Journal: Br J Cancer. 2006 Oct 9;95(7):822-8. Epub 2006 Sep 12.
Abstract URL: Click here to view abstract

100. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group.

Author: Huber RM; Flentje M; Schmidt M; Pollinger B; Gosse H; Willner J; Ulm K;
Institution: Pneumologie, Medizinische Klinik Innenstadt, and Strahlentherapie, University of Munich, Germany. huber@med.uni-muenchen.de
Journal: J Clin Oncol. 2006 Sep 20;24(27):4397-404.
Abstract URL: Click here to view abstract

101. Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.

Author: Saito H; Kudoh S; Nakagawa K; Negoro S; Matsui K; Semba H; Takada M;
Institution: Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki, Japan. hsaito@sun-inet.or.jp
Journal: Am J Clin Oncol. 2006 Oct;29(5):503-7.
Abstract URL: Click here to view abstract

102. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.

Author: Lilenbaum R; Socinski MA; Altorki NK; Hart LL; Keresztes RS; Hariharan S; Morrison ME; Fayyad R; Bonomi P;
Institution: Mount Sinai Cancer Center, Miami Beach, FL 33140, USA. rlilenbaum@aptiumoncology.com
Journal: J Clin Oncol. 2006 Oct 20;24(30):4825-32.
Abstract URL: Click here to view abstract

103. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.

Author: Govindan R; Crowley J; Schwartzberg L; Kennedy P; Williams C; Ekstrand B; Sandler A; Jaunakais D; Bolejack V; Ghalie R;
Institution: Washington University School of Medicine, St Louis, MO 63110, USA. rgovinda@im.wustl.edu
Journal: J Clin Oncol. 2006 Oct 20;24(30):4848-54.
Abstract URL: Click here to view abstract

104. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.

Author: Giaccone G; Gallegos Ruiz M; Le Chevalier T; Thatcher N; Smit E; Rodriguez JA; Janne P; Oulid-Aissa D; Soria JC;
Institution: Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, the Netherlands. g.giaccone@vumc.nl
Journal: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55.
Abstract URL: Click here to view abstract

105. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

Author: Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH;
Institution: Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Journal: J Clin Oncol. 2006 Nov 1;24(31):5025-33.
Abstract URL: Click here to view abstract

106. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.

Author: Ross HJ; Hart LL; Swanson PM; Rarick MU; Figlin RA; Jacobs AD; McCune DE; Rosenberg AH; Baron AD; Grove LE; Thorn MD; Miller DM; Drachman JG; Rudin CM;
Institution: Thoracic Oncology Program, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, #5F40 Portland, OR 97213, United States. hross@orclinic.com
Journal: Lung Cancer. 2006 Oct;54(1):69-77. Epub 2006 Aug 28.
Abstract URL: Click here to view abstract

107. Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.

Author: Ohyanagi F; Taguchi F; Horai T; Kasahara K; Takeda Y; Shibata K; Shirosaki H; Nishio M;
Institution: Thoracic Oncology Center, Cancer Institute Hospital, Koto-ku, Tokyo 135-8550, Japan.
Journal: Jpn J Clin Oncol. 2006 Sep;36(9):547-51. Epub 2006 Jul 26.
Abstract URL: Click here to view abstract

108. Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status.

Author: Norsa A; Martino V;
Institution: Thoracic Surgery Unit, Ospedale Maggiore Azienda Ospedaliera, Verona, Italy. norsaachille@yahoo.it
Journal: Cancer Biother Radiopharm. 2006 Feb;21(1):68-73.
Abstract URL: Click here to view abstract

109. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.

Author: Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
Institution: University of California, Davis, Sacramento, CA, USA. angela.davies@ucdmc.ucdavis.edu
Journal: J Clin Oncol. 2006 Nov 20;24(33):5242-6.
Abstract URL: Click here to view abstract

110. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.

Author: Paz-Ares L; Douillard JY; Koralewski P; Manegold C; Smit EF; Reyes JM; Chang GC; John WJ; Peterson PM; Obasaju CK; Lahn M; Gandara DR;
Institution: Servicio de Oncologia Medica, Doce de Octubre University Hospital, Madrid, Spain. lpaz.hdoc@salud.madrid.org
Journal: J Clin Oncol. 2006 Mar 20;24(9):1428-34.
Abstract URL: Click here to view abstract

111. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

Author: West HL; Franklin WA; McCoy J; Gumerlock PH; Vance R; Lau DH; Chansky K; Crowley JJ; Gandara DR;
Institution: Swedish Cancer Institute/Puget Sound Oncology Consortium, Seattle, WA, USA.
Journal: J Clin Oncol. 2006 Apr 20;24(12):1807-13.
Abstract URL: Click here to view abstract

112. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.

Author: Stathopoulos GP; Katis C; Tsavdaridis D; Dimitroulis J; Karaindros D; Stathopoulos J; Dimou E;
Institution: First Oncology Department, Errikos Dunant Hospital, Athens, Greece. dr-gps@ath.forthnet.gr
Journal: Cancer Chemother Pharmacol. 2006 Oct;58(4):555-60. Epub 2006 Mar 7.
Abstract URL: Click here to view abstract

113. Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer.

Author: Feliu J; Martin G; Castro J; Sundlov A; Rodriguez-Jaraiz A; Casado E; Lomas M; Madronal C; Galan A; Belda C; Gonzalez-Baron M;
Institution: Servicio de Oncologia Medica, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain. jaimefeliu@hotmail.com
Journal: Cancer Chemother Pharmacol. 2006 Oct;58(4):527-31. Epub 2006 Mar 23.
Abstract URL: Click here to view abstract